Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation
JUPITER, Fla., Oct. 9, 2017 /CNW/ -- Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at flexible commercial scales, is now available for on-demand viewing at VirtualInvestorConferences.com.
Dyadic International's presentation will be available 24/7 for 90 days. Investors and advisors may download shareholder materials from the "virtual trade booth" for the next three weeks.
Recent Company Highlights
- On August 16, 2017, the Company announced that its Board of Directors has authorized a new stock repurchase program, under which the Company may repurchase up to $5 million of its outstanding common stock
- As of June 30, 2017, the Company's cash, cash equivalents and investment grade securities, including interest receivable, was approximately $45.6 million (excluding approximately $7.4 million of escrowed funds). On July 6, 2017, the Company received approximately $7.4 million of cash held in escrow in connection with the previously announced DuPont Transaction
- As of June 30, 2017, there were approximately 28.7 million shares outstanding and approximately 10.2 million shares held in treasury
- On June 30, 2017, the Company entered into a strategic research and collaboration agreement, including a potential commercialization agreement, with Biotechnology Development for Industry ("BDI"), a Spanish biotech company, and its subsidiaries, to advance Dyadic's proprietary C1 technology in the development of next generation biological vaccines and drugs
- On May 4, 2017, the Company entered into a fully funded research program with one of the world's largest pharmaceutical companies, which is focused on demonstrating the potential of the C1 technology to produce therapeutic proteins
Learn more about the event at www.VirtualInvestorConferences.com.
About Dyadic International, Inc.
Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical protein production system based on the fungus Myceliophthora thermophila, nicknamed C1. The C1 microorganism, which enables the development and large scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, production and performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines, monoclonal antibodies, biosimilars and/or biobetters, and other therapeutic proteins. Dyadic pursues research & development collaborations, licensing arrangements and other commercial opportunities with its partners and collaborators to leverage the value and benefits of these technologies in developing and manufacturing biopharmaceuticals which these technologies help produce. In particular, as the aging population grows in developed and undeveloped countries, Dyadic believes the C1 technology may help bring biologic drugs to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers and, hopefully, improve access and cost to patients and the healthcare system, but most importantly save lives.
Please visit Dyadic's website at www.dyadic.com for additional information, including details regarding Dyadic's plans for its biopharmaceutical business.
Dyadic trades on the OTCQX tier of the OTC marketplace. Investors can find real-time quotes, market information and financial reports for Dyadic in the Company's annual and quarterly reports which are filed with the OTC markets. Please visit the OTC markets website at www.otcmarkets.com/stock/DYAI/quote.
Safe Harbor Regarding Forward-Looking Statements
Certain statements contained in this press release are forward-looking statements within the meaning of the federal securities laws. These forward-looking statements involve risks, uncertainties and other factors that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Investors are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. Any forward-looking statements speak only as of the date of this press release and, except as required by law, Dyadic expressly disclaims any intent or obligation to update or revise any forward-looking statements to reflect actual results, any changes in expectations or any change in events. Factors that could cause results to differ materially include, but are not limited to: (1) general economic, political and market conditions; (2) our ability to carry out and implement our biopharmaceutical research and business plans and strategic initiatives; (3) Dyadic's ability to retain and attract employees, consultants, directors and advisors; (4) our ability to implement and successfully carry out Dyadic's and third parties research and development efforts; (5) our ability to obtain new license and research agreements; (6) our ability to maintain our existing access to, and/or expand access to third party contract research organizations in order to carry out our research projects for ourselves and third parties; (7) competitive pressures and reliance on key customers and collaborators; and (8) other factors discussed in Dyadic's publicly available filings, including information set forth under the caption "Risk Factors" in our December 31, 2016, Annual Report filed with OTC Markets on March 24, 2017. New risks and uncertainties arise from time to time, and it is impossible for us to predict these events or how they may affect us.
Since 2010, VirtualInvestorConferences.com, created by BetterInvesting (NAIC) and PRNewswire, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with investors using a graphically-enhanced online platform.
Designed to replicate the look and feel of location-based investor conferences, Virtual Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.
SOURCE Dyadic International, Inc.
For further information: Dyadic International, Dyadic International, Inc. , Thomas L. Dubinski , Chief Financial Officer , Phone: 561-743-8333 , Email: firstname.lastname@example.org; VirtualInvestorConferences.com, John Viglotti, VP, Investor Relations Products and Services, Cision / PR Newswire / MultiVu, 350 Hudson Street | 3rd Floor | New York, NY 10014, Phone: 201 360 6767 | Mobile: 212 729 8350, Email: email@example.com